Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
<p dir="ltr">Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better overall survival,...
محفوظ في:
مواد مشابهة
-
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
حسب: Maha, Al-Asmakh
منشور في: (2020) -
Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
حسب: Maha Al-Asmakh (614593)
منشور في: (2021) -
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
حسب: Reem Saleh (3513056)
منشور في: (2019)